While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol ...

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Indeed, there weren’t many more biotech IPOs in 2024 than in 2023, and the companies that did venture out this year struggled ...

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 ...